Connect with us

Coronavirus Outbreak

COVID Vaccines Effective Against Delta Variant, UK Study Finds

The study by scientists at the University of Oxford, involving more than 700,000 randomly selected people from within the community, found that the Pfizer/BioNTech and Oxford/AstraZeneca Covid vaccines still offer good protection against new infections

COVID Vaccines Effective Against Delta Variant, UK Study Finds
Highlights
  • Oxford vaccine is being produced and administered in India as Covishield
  • More viral load hints towards herd immunity being more challenging: Study
  • Time between doses does not affect effectiveness: Study

London: Obtaining two vaccine doses remains the most effective way to ensure protection against the COVID-19 Delta variant of concern (VOC), first identified in India and now dominant in the UK, one of Britain’s largest studies of its kind concluded on Thursday (August 19). The study by scientists at the University of Oxford, involving more than 700,000 randomly selected people from within the community, found that the Pfizer/BioNTech and Oxford/AstraZeneca vaccines still offer good protection against new infections.

Also Read: What Is Being Done To Distribute COVID-19 Vaccines Globally?

The Oxford/AstraZeneca vaccine is being produced and administered in India as Covishield.

With Delta, Pfizer/BioNTech and Oxford/AstraZeneca vaccines still offer good protection against new infections, but effectiveness is reduced compared with Alpha (first identified in England last year and previously the dominant VOC in the UK), read the findings released by the university’s Nuffield Department of Medicine.

“Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 before through natural infection; people who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 before,” it notes.

However, the higher infectiousness of the Delta variant was also confirmed as it was found that infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people; with the Alpha variant, peak virus levels in those infected post-vaccination were much lower.

“The vaccines are better at preventing severe disease and are less effective at preventing transmission,” said Dr Koen Pouwels, one of the lead researchers of the study.

The fact that you see more viral load (with the Delta variant) hints towards herd immunity being more challenging, he said.

Also Read: Benefits Of COVID Vaccines Far Outweigh Rare Risk Of Facial Paralysis, Lancet Study Confirms

In other findings, the study reveals that a single dose of the Moderna vaccine has similar or greater effectiveness against the Delta variant as single doses of the other vaccines. Also, two doses of Pfizer/BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford/AstraZeneca.

Results suggest that after four to five months, the effectiveness of these two vaccines would be similar – however, long-term effects need to be studied, it notes.

The Pfizer/BioNTech vaccine had 93 per cent effectiveness against symptomatic infection two weeks after the second dose, compared with Oxford/AstraZeneca’s 71 per cent. Over time, however, Pfizer/BioNTech’s effectiveness dropped while Oxford/AstraZeneca’s remained largely the same.

Experts point out that both vaccines are well within the World Health Organisation (WHO) bar of 50 per cent and therefore continue to offer good protection against COVID-19. It was also noted that the time between doses does not affect effectiveness in preventing new infections, but that younger people have even more protection from vaccination than older people. The researchers analysed two and a half million test results from 743,526 participants in the UK’s Covid-19 household-infection survey – led by Oxford University and the Office for National Statistics (ONS).

Also Read: No Data Shows Need For Booster COVID-19 Vaccines Presently: Dr Gagandeep Kang

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

26,43,68,460Cases
22,50,84,762Active
3,40,45,666Recovered
52,38,032Deaths
Coronavirus has spread to 196 countries. The total confirmed cases worldwide are 26,43,68,460 and 52,38,032 have died; 22,50,84,762 are active cases and 3,40,45,666 have recovered as on December 3, 2021 at 1:36 pm.

India

3,46,15,757 9,216Cases
99,976 213Active
3,40,45,666 8,612Recovered
4,70,115 391Deaths
In India, there are 3,46,15,757 confirmed cases including 4,70,115 deaths. The number of active cases is 99,976 and 3,40,45,666 have recovered as on December 3, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

66,37,221 796

10,882 180

64,85,290 952

1,41,049 24

Kerala

51,51,919 4,700

45,030 252

50,66,034 4,128

40,855 320

Karnataka

29,96,833 363

6,772 169

29,51,845 191

38,216 3

Tamil Nadu

27,28,350 715

8,155 45

26,83,691 748

36,504 12

Andhra Pradesh

20,73,252 159

2,138 11

20,56,670 169

14,444 1

Uttar Pradesh

17,10,417 12

93 1

16,87,413 11

22,911

West Bengal

16,17,408 657

7,690 22

15,90,208 667

19,510 12

Delhi

14,41,190 217

307 21

14,15,785 196

25,098

Odisha

10,49,597 252

2,211 26

10,38,971 276

8,415 2

Chhattisgarh

10,06,870 37

328 12

9,92,949 25

13,593

Rajasthan

9,54,827 21

213 10

9,45,659 11

8,955

Gujarat

8,27,570 50

318 25

8,17,158 24

10,094 1

Madhya Pradesh

7,93,199 12

128 4

7,82,543 8

10,528

Haryana

7,71,760 27

178 9

7,61,528 18

10,054

Bihar

7,26,230 5

32 0

7,16,534 4

9,664 1

Telangana

6,76,376 189

3,680 50

6,68,701 137

3,995 2

Assam

6,17,163 124

2,535 77

6,08,517 198

6,111 3

Punjab

6,03,352 32

344 13

5,86,402 18

16,606 1

Jharkhand

3,49,271 15

95 1

3,44,035 13

5,141 1

Uttarakhand

3,44,325 22

182 4

3,36,735 18

7,408

Jammu And Kashmir

3,37,263 177

1,697 10

3,31,089 167

4,477

Himachal Pradesh

2,27,354 85

835 29

2,22,669 113

3,850 1

Goa

1,79,046 56

367 40

1,75,295 16

3,384

Mizoram

1,35,765 315

3,717 55

1,31,545 368

503 2

Puducherry

1,28,998 33

299 10

1,26,826 23

1,873

Manipur

1,25,269 33

663 4

1,22,627 28

1,979 1

Tripura

84,835 15

94 6

83,916 8

825 1

Meghalaya

84,534 24

296 2

82,764 25

1,474 1

Chandigarh

65,475 4

65 1

64,590 5

820

Arunachal Pradesh

55,285 6

36 1

54,969 5

280

Sikkim

32,267 15

137 10

31,727 5

403

Nagaland

32,128 3

128 5

31,302 6

698 2

Ladakh

21,642 41

306 21

21,122 20

214

Dadra And Nagar Haveli

10,683

0 1

10,679 1

4

Lakshadweep

10,397 1

18 8

10,328 9

51

Andaman And Nicobar Islands

7,686 3

7 2

7,550 1

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Highlights From The 12-Hour Telethon

Leaving No One Behind

Mental Health

Environment

Join Us